News

News

Long-Term Follow-Up Confirms Safety, Efficacy of Imatinib for CML

Early results (published in Leukemia in 2009) from the phase III International Randomized Study of Interferon and STI571 (IRIS) demonstrated that imatinib 400 mg...

Marching for Science, ASH Announces Physician-Scientist Career Development Award Recipients, and more

Marching for Science The first March for Science, which took place Saturday, April 22, 2017, in more than 600 locations around the world, drew hundreds...

Long-Term Study Highlights Limitations of Current TTP Diagnostic Methods

For the past two decades, ADAMTS13 activity has been the backbone of diagnosis for thrombotic thrombocytopenic purpura (TTP); however, a long-term registry study published...

Deep Response With Venetoclax Plus Rituximab in Relapsed/Refractory CLL

Combining the selective BCL2 inhibitor venetoclax with rituximab may increase the depth and durability of response in patients with relapsed/refractory chronic lymphocytic leukemia (CLL),...
WIB_icon

Predicting Survival Outcomes for Children With Down Syndrome and AML or MDS

Children with Down syndrome (DS) have a higher risk of developing acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML) than those without DS....
WIB_icon

Weighing the Risks and Benefits of Nivolumab in Patients With Hodgkin Lymphoma Undergoing AlloHCT

For patients with Hodgkin lymphoma (HL), allogeneic hematopoietic cell transplantation (alloHCT) can induce long-term disease control; however, relapse is common and rates of 3-year...
WIB_icon

Pembrolizumab Induces Remission in Small Cohort of Patients With Natural Killer/T-Cell Lymphomas

For the 20 to 40 percent of patients with natural killer (NK)/T-cell lymphomas who do not respond to regimens such as SMILE (dexamethasone, methotrexate,...
WIB_icon

Venetoclax Plus Obinutuzumab Effective in Older Adults With CLL and Comorbidities

Patients with chronic lymphocytic leukemia (CLL) are often older at the time of diagnosis (median age = 72 years), and typically receive treatment for...
WIB_icon

Is Ibrutinib Tied to Ventricular Arrhythmias?

Previous studies have indicated that treatment with ibrutinib, a Bruton tyrosine kinase (BTK) inhibitor, is associated with a 5 to 15 percent increase in...

ACS Announces Lane W. Adams Quality of Life Award Winners, 2017 Eric G. Neilson,...

ACS Announces Lane W. Adams Quality of Life Award Winners The ACS honored six cancer caregivers with the Lane W. Adams Quality of Life Award,...
Advertisement

Current Issue

May 2017, Volume 3, Issue 6

This issue discusses the legacy of Agent Orange and hematologic malignancies, a debate over transplant in myelodysplastic syndromes, and more.